<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489710</url>
  </required_header>
  <id_info>
    <org_study_id>401-05</org_study_id>
    <secondary_id>CDR0000549510</secondary_id>
    <nct_id>NCT00489710</nct_id>
  </id_info>
  <brief_title>Talabostat in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase II Study of Talabostat in Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Talabostat may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well talabostat works in treating patients with&#xD;
      metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with metastatic renal cell carcinoma treated&#xD;
           with talabostat mesylate.&#xD;
&#xD;
        -  Determine the progression-free survival of patients treated with this drug.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of this drug in these patients.&#xD;
&#xD;
        -  Correlate changes in specific cytokine levels and peripheral blood flow cytometry with&#xD;
           progression-free survival.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized study.&#xD;
&#xD;
      Patients receive oral talabostat mesylate once daily on days 1-14. Courses repeat every 21&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are obtained from patients at baseline and after each course for biomarker&#xD;
      correlative studies. Samples are analyzed for serum cytokines and chemokines and for T-cell&#xD;
      subsets and NK cells by flow cytometry. Peripheral blood lymphocytes are obtained at baseline&#xD;
      and after course 1 for future assessment by gene microarray analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Terminated for safety reasons&#xD;
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>At progression or death from any cause</time_frame>
    <description>Kaplan-Meier method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>At 9 and 12 evaluable patients</time_frame>
    <description>Evaluable patients are those that have completed 4 cycles of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicity</measure>
    <time_frame>At end of each course</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events as assessed by NCI CTCAE v3.0</measure>
    <time_frame>At end of each course</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Talabostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Talabostat 600 mcg PO QD x 14 days (21 day cycle); 2 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>talabostat mesylate</intervention_name>
    <arm_group_label>Talabostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diagnostic procedure</intervention_name>
    <arm_group_label>Talabostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>enzyme inhibitor therapy</intervention_name>
    <arm_group_label>Talabostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <arm_group_label>Talabostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Talabostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>non-specific immune-modulator therapy</intervention_name>
    <arm_group_label>Talabostat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Pathologic diagnosis of renal cell carcinoma&#xD;
&#xD;
               -  Clinical confirmation of metastatic disease required&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
             conventional techniques or ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  The following are considered nonmeasurable disease:&#xD;
&#xD;
                    -  Small lesions (longest diameter &lt; 20 mm by conventional techniques or &lt; 10&#xD;
                       mm by spiral CT scan)&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural or pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis or pulmonis&#xD;
&#xD;
                    -  Abdominal masses that are not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  Progressed after ≥ 1 multikinase inhibitor regimen (i.e., sorafenib tosylate or&#xD;
             sunitinib malate)&#xD;
&#xD;
          -  No history of CNS or brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL (no packed red blood cell transfusions within the past 4 weeks)&#xD;
             (epoetin alfa support allowed)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times the upper limit of normal (ULN) (unless due to Gilbert's&#xD;
             syndrome)&#xD;
&#xD;
          -  AST and ALT ≤ 3 times ULN&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  No active serious infections&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell or nonmetastatic&#xD;
             squamous cell skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No comorbidity or concurrent condition that would interfere with protocol assessments&#xD;
             or procedures&#xD;
&#xD;
          -  No ongoing coagulopathy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior systemic therapy and recovered&#xD;
&#xD;
          -  Prior radiotherapy allowed as long as the lesion treated is not used to assess&#xD;
             response&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 50% of the bone marrow&#xD;
&#xD;
          -  No prior radiotherapy to index lesions unless there is clearly progressive disease&#xD;
             within the irradiated area OR measurable disease outside the irradiated area&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Hauke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Ralph Hauke</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

